Background/Aim: At present, there are no biomarkers to predict the effects of molecular targeted drugs in patients with CRC with liver metastasis. Thus, we performed this study to explore potential biomarkers for these patients. Materials and Methods: We obtained cancer tissue specimens from liver metastasis-bearing CRC patients who received the following preoperative neoadjuvant chemotherapies with molecular targeted drugs: i) no therapy (n=3), ii) 5-FU+oxaliplatin+anti-EGFR (n=3), iii) and 5-FU+oxaliplatin+anti-VEGF (n=3). Results: We investigated the RNA expression of 84 genes related to cancer drug resistance using an RT-PCR array. The MYC gene was the only gene that was significantly up-regulated in CRC tissue specimens from anti-EGFR group in comparison to the anti-VEGF group. Conclusion: MYC up-regulation in the primary CRC tissues may be a potentially useful biomarker for selecting anti-EGFR combination therapy in neoadjuvant chemotherapy for CRC with liver metastasis.

中文翻译：

---

MYC 上调是结直肠癌肝转移术前新辅助化疗联合抗 EGFR 的有用生物标志物

背景/目的：目前还没有生物标志物可以预测分子靶向药物对结直肠癌肝转移患者的影响。因此，我们进行了这项研究以探索这些患者的潜在生物标志物。材料和方法：我们从接受以下分子靶向药物术前新辅助化疗的肝转移癌患者中获取癌组织标本：i）未治疗（n=3），ii）5-FU+奥沙利铂+抗EGFR（ n=3)、iii)和5-FU+奥沙利铂+抗-VEGF（n=3）。结果：我们使用 RT-PCR 阵列研究了 84 个与癌症耐药性相关的基因的 RNA 表达。与抗 VEGF 组相比，MYC 基因是唯一在来自抗 EGFR 组的 CRC 组织标本中显着上调的基因。结论：